Issue: October 2013 , Posted Date: 10/15/2013

FORMULATING PEPTIDES - Novel Formulations for Non-Invasive Delivery & Stabilization of Peptides

 
 

INTRODUCTION

 

Since the discovery of insulin and its therapeutic application to the treatment of diabetes early in the 20th century, proteins and peptides have held enormous attraction as potential therapeutic agents. Many peptides demonstrate high potency and selectivity while exhibiting essentially no chemical toxicity as they metabolize to naturally occurring amino acids. In spite of the many attractive aspects of peptides and proteins as potential therapeutics, their susceptibility to denaturation and hydrolysis in the gastrointestinal tract has necessitated administration by injection, and this remains their major shortcoming as drugs. As a result, while the range of clinical indications for therapeutic peptides and proteins is substantial, the actual number of such therapeutics in general use today, though growing, is quite small compared with the number of chemically synthesized orally bioavailable small molecule drugs.

 

Literally dozens of excipients have been tested as potential enhancers of transmucosal absorption in the hope that alternate non-invasive means of administering peptides and proteins might be achieved. Some examples are shown in Table 1. The majority of these excipients have proven to be damaging to mucosal tissue upon repeated administration, especially at concentrations high enough to achieve a substantial degree of transmucosal absorption enhancement. The few exceptions, which include chitosan, various cyclodextrins, EDTA, and propylene glycol, have been found to be generally well tolerated, but not substantially effective as absorption enhancers.



 

Certain alkylsaccharides were found by scientists at the University of Alabama Medical Ctr., Birmingham, to significantly increase transmucosal absorption of peptides and proteins up to about 30 kDa in size, as well as poorly absorbed small molecule drugs, allowing non-invasive delivery via the intranasal, oral, and buccal administration routes.1-4

 

These same excipients have been shown to effectively prevent aggregation during manufacturing and in final formulations and may serve as non-oxidizing and non-damaging replacements for polysorbates in biotherapeutic formulations.5

 

CHARACTERISTICS OF ALKYLSACCHARIDES

 

Alkylsaccharides composed of disaccharides and alkyl chain substituents with lengths between 10 and 16 carbons have been shown to be among the most effective transmucosal absorption enhancers for peptides, proteins, and small molecule drugs. Two classes of alkylsaccharides in particular, alkylglycosides, most notably tetradecyland dodecyl maltoside, and alkyl esters, especially sucrose monododecanoate (Figure 1), have been found to be particularly useful and effective, combining unmatched absorption enhancement with a high degree of safety and lack of toxicity. More recently, they have been demonstrated to be highly effective in preventing peptide and protein aggregation and stabilizing proteins against denaturation under conditions of elevated temperatures andmechanical stress.6 The alkylsaccharides of interest happen to be designated as GRAS (Generally Recognized as Safe) substances for food applications although not specifically for pharmaceutical use.7,8 For absorption enhancement, they function by allowing controlled transient mucosal permeation by both paracellular (tight-junction) and transcellular routes.2,9 For aggregation prevention, they function like other surfactants in covering exposed hydrophobic sites prone to aggregation and presenting a hydrophilic face in their place. Once administered, they metabolize rapidly to the corresponding free sugars and fatty acids or corresponding long-chain fatty alcohols. The pharmaceutical grade of these alkylsaccharides manufactured under GMP in FDA-licensed facilities are designated as Intravail® or ProTek® excipients. The general characteristics of these specific alkylsaccharides are summarized in Table 2.

 









NON-INVASIVE DELIVERY
APPLICATIONS

 

Alkylsaccharides Enhance Intranasal Drug Delivery

Alkylsaccharides circumvent the two primary limitations of intranasal drug delivery experienced in the past, namely mucosal irritation and poor bioavailability, and have been shown to be highly effective in increasing systemic absorption of nasally administered drugs. Published examples of absorption enhancement for proteins ranging from 4,000 Da to 30,000 Da in preclinical studies are summarized in Figure 2.1,2 For peptides and proteins up to approximately 20 kDa, intranasal bioavailabilities in excess of 50% compared with injection can be attained. For smaller peptides, such as calcitonin, bioavailabilities in excess of 95% are observed.



 

Human clinical studies conducted with PTH 1 to 31 and calcitonin, as well as with the small molecule drugs sumatriptan and diazepam yielded systemic bioavailabilities of 35% to 37% for the peptides and up to 96% absolute bioavailability for the small molecules.10-13 Improved non-invasive systemic absorption allows drug companies to embrace the broader use of peptides as commercially and clinically viable human therapeutics and promises to offer patients new, more convenient, and more effective therapeutic options across a broad spectrum of human diseases.

 

For companies with existing franchises in protein or peptide therapeutics, non-invasive formulations of existing injectables may provide a rapid path to regulatory approval and near-term increased revenues.

 

Alkylsaccharides Enhance Oral Delivery

The use of alkylsaccharides in oral delivery of peptide drugs has only been demonstrated at the preclinical level. In studies by Grasso et al at Albany Medical College, the investigators demonstrated oral delivery of D-Leu-OB3, a linear 7- mer peptide with anti-obesity and anti-diabetes activity and octreotide, a cyclic 8-mer, with bioavailabilities in excess of 50% to 100%, respectively, compared to subcutaneous or intraperitoneal injection.14-16 Oral absorption of exenatide and pramlintide have also been recently reported.17,18

 

BIOTHERAPEUTIC FORMULATION APPLICATIONS

 

Aggregation is well understood to be a key factor underlying multiple deleterious effects for peptide and protein-based therapeutics, including reduced stability or product shelf-life, reduced manufacturing yields, and most significantly, induction of unwanted immunogenicity. Neutralizing antibodies may result in decreased biotherapeutic efficacy, altered pharmacokinetics, or elimination of residual intrinsic activity of a patient’s own native protein. Two of the most severe clinical examples include anti-EPO antibodies causing lethal “pure red cell aplasia” and anti-Factor VIII antibodies causing life-threatening bleeding, necessitating prolonged tolerance-inducing therapy to reverse immunity.19-21 Other examples of clinically detrimental immune responses have been reported for beta-interferon, thrompoietin, GM-CSF, IL-17, and mAbs, including infliximab, rituximab, adalimumab, natalizumab, and TNF-specific monoclonal antibodies.

 

Protein aggregation is a principal cause of unwanted immunogenicity and immunogenicity of peptide therapeutics is a significant and growing concern of the FDA and EMA. In comments from the FDA Public Hearing on Biosimilars in May 2012, Richard Dolinar, MD, Chairman, Alliance for Safe Biologic Medicines stated: “Unwanted immunogenicity is the preeminent safety challenge associated with all biological therapeutics and can result in unexpected and sometimes severe adverse effects. Complicating matters, side-effects may only appear in patients after higher doses or prolonged duration of treatments and may be attributed to a number of patient-, disease-, or product-related factors.” The full testimony may be accessed online at http://www.safebiologics.org/pdf/FDA/ASBM-Testimony.pdf.

 

Determination of the immune response of new innovator biotherapeutics and biosimilars will have significant impact on the clinical trial and regulatory approval processes. To address these problems, surfactants are routinely incorporated into many biotherapeutic formulations to prevent aggregation, improve reproducibility upon reconstitution of lyophilizates, and prevent loss due to stickiness on filters, columns, and container surfaces.

 

PROBLEMS WITH CURRENTLY USED SURFACTANTS

 

The surfactant most commonly employed in biotherapeutics today is polysorbate 80. Polysorbate 80 has proven highly effective in preventing protein aggregation; however, it is subject to certain serious limitations that are becoming increasingly apparent to formulation chemists within the pharmaceutical industry as well as regulatory authorities.



 

Polysorbates and other polyoxyethylene-based surfactants that contain ether linkages (polyoxyethylene moieties) and unsaturated alkyl chains spontaneously and rapidly autooxidize in aqueous solution to protein-damaging peroxides, epoxy acids, and reactive aldehydes. These chemically reactive species modify methionines, histidines, tryptophans, as well as any primary amines or accessible nucleophiles, such as those found in cysteine and tyrosine (Table 3), creating neoantigens that cause unwanted immunogenicity and in some instances promote re-aggregation. Unlike alkylsaccharides, which can be manufactured as pure single chemical species, polysorbates are mixtures of structurally related fatty acid esters of polyoxyethylene sorbitan. The principal fatty acids, lauric acid, and oleic acid, comprise up to 60% of the total fatty acid composition with esters of fatty acids of other chain lengths making up the remainder of the molecules.22 In addition to the oxidative contaminants previously described, commercial polysorbate preparations contain measurable amounts of polyoxyethylene, polyoxyethylene sorbitan, and isosorbide polyoxyethylene fatty acid esters.22-24 The structure of polysorbate 80 is shown in Figure 3. There is a great deal of lot-to-lot variation in the nature and content of oxidative species found in different polysorbate lots. For example, an analysis of 14 lots of polysorbate 80 from four different manufacturers showed a 26-fold range in hydroperoxide content (ie, from 290 nmole/g to 7,700 nmole/g; average: 1,807 nmole/g).25 The level of reactive contaminants in polysorbate preparations varies over time as autoxidation of polysorbates is spontaneousand progressive. This variability would seem to be a likely contributor to lot-to-lot variability in immunogenicity, which may crop up in post-market surveillance - undoubtedly a potential concern for biotherapeutics manufacturers.


 


High purity preparations of polysorbate
80 treated to remove peroxides and packaged with oxygen excluded from the container headspace using nitrogen or argon are available commercially; however, oxidation resumes as soon as there is any contact with oxygen and the oxidation reaction accelerates once polysorbates are placed into aqueous solution. Typically, reactive species are detectable within 1 or 2 weeks following purification.

 

Measurement of residual reactive contaminants in biotherapeutic products is not meaningful because the reactive species are consumed in their reactions with the amino acyl side chains in forming neo-antigens. Thus, actual assessment of the degree of protein damage will require detection and measurement of the modified aminoacyl groups in the biotherapeutic over the course of time if it becomes necessary to assess the immunogenicity potential of each lot of a biotherapeutic prior to release into inventory.

 

Alkylsaccharides as Non-Oxidizing Alternative Surfactants

Alkylsaccharides afford a possible alternative and are increasingly finding their way into biotherapeutic formulation work because they are highly effective in preventing protein aggregation, but are not subject to development of contaminating oxidative species. For example, the stabilization of recombinant human insulin (Humulin®R, Eli Lilly) at two concentrations of alkylsaccharide (ProTek® excipient) is shown in Figure 4. In each case, the protein was subjected to accelerated stress by continuous shaking at 150 RPM at 37°C for up to 90 days. The untreated Humulin is seen to begin denaturing in less than 1 day of constant agitation as measured by increased light scatter – a technique routinely used to measure protein aggregation. In contrast, the ProTek alkylsaccharide excipient at both concentrations tested prevented denaturation for the full 90-day test period of the study. The non-ProTek alkylsaccharide also tested in this study (an isomer with the same sugar and alkyl chain moieties), provided limited protection up to about 2 or 3 weeks. Similarly, increased stability of human growth hormone, beta interferon 1a, beta interferon 1b, pramlintide, parathyroid hormone 1-34 and 1-31(cyclic), monoclonal antibodies, and a linear 8-mer CCR5 inhibitor prone to rapid and severe aggregation has been demonstrated.26



 


FUTURE OPPORTUNITIES & CHALLENGES

 

Alkylsaccharides offer exciting prospects for novel formulations, providing non-invasive delivery, stabilization, and immunogenicity reduction for biotherapeutic products. Non-invasive delivery of peptide and protein drugs will provide opportunities for broader patient acceptance and compliance with novel peptide therapeutics and may be expected to lead to an increase in the acceptance of peptide therapeutics as viable commercial pharmaceuticals.

 

Substitution of polysorbates with a suitable non-oxidizing alkylsaccharide surfactant could in effect yield biosimilars that are truly “biosuperior” to the corresponding polysorbate-containing innovator or biosimilar products with respect to no or low immunogenicity, increased stability, consistent and predictable efficacy, and extended shelf-life. As with any new excipient, there is a regulatory requirement for extensive preclinical and clinical studies to be conducted prior to regulatory approval. The extent of such studies (eg, type, duration, number of species) is determined by the FDA and depends on the mode of use (chronic or acute), frequency of dosing, and route of administration. Such studies are underway for some applications (eg, monoclonal antibodies), and we can reasonably expect that future research will be undertaken to discover additional alternatives to address theneed for aggregation prevention withoutconcomitant oxidative damage.

 

REFERENCES

 

1. Ahsan F, Arnold J, Meezan E, Pillion DJ. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm Res. 2001;18(12):1742-1746.

2. Arnold JJ, Ahsan F, Meezan E, Pillion DJ. Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J Pharm Sci. 2004;93(9):2205-2213.

3. Arnold JJ, Fyrberg MD, Meezan E, Pillion DJ. Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-b-D-maltoside. J Pharm Sci. 2010;(4):1912-1920.

4. Maggio ET, Pillion DJ. High efficiency intranasal drug delivery using Intravail® alkylsaccharide absorption enhancers. Drug Delivery Translational Research. 2013;3:16-25.

5. Maggio ET. Polysorbates, peroxides, protein aggregation, and immunogenicity - a growing concern. J Excip Food Chem. 2012;3(2),45-53.

6. Maggio ET. Use of excipients to control aggregation in peptide and protein formulations. J Excip Food Chem. 2010;1:40-49.

7. Alkyl (C10-C16) polyglycosides; exemptions from the requirement of a tolerance. Federal Register: September 14, 2005 (Vol.70, No. 177):54281-54286.

8. Sucrose esters of fatty acids and sucroglycerides (WHO Food Additives Series 40). The 49th meeting of the Joint FAO/ WHO Expert Committee on Food Additives (JECFA) Geneva 1998. http://www.inchem.org/documents/ jecfa/jecmono/v040je04.htm.

9. Chen SC, Eiting KT, Li AAW, Lamharz N, Quay SC. Identification of tight junction modulating lipids. J Pharm Sci. 2009;98(2):606-619.

10. Eddy P, Krause D, Merutka G, MacDonald B. Intranasal (IN) pharmacokinetics (PK) and bioavailability of ZT-031, a novel parathyroid hormone (PTH) analog. ASBMR Poster Presentation Number: MO0385. September 14, 2009.

11. Maggio ET, Meezan E, Ghambeer DKS, Pillion DJ. High bioavailability formulation of salmon calcitonin - potential opportunities for expanded use in analgesia. Drug Delivery Technology. 2010;10:58-63.

12. Maggio ET. Alkylglycoside compositions for drug adminisation. US Patent No. 8,268,791. Issued September 18, 2012.

13. Neurelis announces positive results from phase 1 pharmacokinetic study of NRL-01 (intranasal diazepam) http://www.bizjournals.com/prnewswire/press_releases/2011/06/14/LA19174. Accessed 15 April 2012.

14. Lee DW, Leinung MC, Grasso P. OB3 oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration. Regul Pept. 2010;160:129-132.

15. Novakovic ZM, Leinung MC, Lee DW, Grasso P. Oral delivery of mouse [DLeu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycemic control and serum osteocalcin levels. Diabetes Obes Metab. 2010;12:532-539.

16. Maggio ET, Grasso P. Oral delivery of octreotide acetate in Intravail improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss Webster mice. Regul Pept. 2011;167:233-238.

17. Leinung MC, Grasso P. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide (Byetta®) and pramlintide (Symlin®) on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice. Regul Pept. 2012;179(1-3):33-38.

18. Novakovic ZM, Leinung MC, Grasso P. [D-Leu-4]-OB3, an orally bioavailable leptin-related synthetic peptide insulin sensitizer: a study comparing the efficacies of [D-Leu-4]-OB3 and metformin on energy balance

and glycemic regulation in insulin-deficient male Swiss Webster mice. Peptides. 2013;43:167-173.

19. Casadevall N, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. NEJM. 2002;346:469-475.

20. Purohit VS, Middaugh CR, Balasubramanian SV. Influence of aggregation on immunogenicity of recombinant human factor VIII in hemophilia A mice. J Pharm Sci. 2006;95:358-371.

21. Reipert BM, et al. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haemophilia. 2007;136:12-25.

22. Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharm Sci.  2008;97:2924-2935.

23. Ayorinde FO, Gelain SV, Johnson JH, Jr., Wan LW. Analysis of some commercial polysorbate formulations using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 2000;14(22):2116-2124.

24. Brandner JD. The composition of NF-defined emulsifiers: sorbitan monolaurate, monopalmitate, monostearate, monooleate, polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80. Drug Dev Ind Pharm.

1998;24(11):1049-1054.

25. Wasylaschuk WR, Harmon PA, Wagner G, et al. Evaluation of hydroperoxides in common pharmaceutical excipients. J Pharm Sci. 2007;96:106-116.

26. Maggio ET. Stabilizing alkylglycoside compositions and method thereof. US Pat. No. 8,226,949. Issued July 24, 2012.

 

 

Dr. Edward T. Maggio is CEO of Aegis Therapeutics. He has been a founder and board member of seven public and private life science companies in the San Diego area and one in Copenhagen, Denmark. He earned his PhD from the University of Michigan and was an NIH post-doctoral fellow at the University of California, San Francisco (UCSF), Department of Pharmaceutical Chemistry. He is a member of the Advisory Board of the Polytechnic Institute of New York University, Department of Chemical and Biological Sciences; the University of California, San Diego, Dean’s Board of Advisors for Biological Sciences; the California State University, San Marcos, Biotechnology Programs Advisory Board; and the Industry Council of the San Diego Consortium for Regenerative Medicine; the Editorial Board of the Journal of Excipients and Food Chemicals, and a reviewer for the journals Diabetes, Obesity and Metabolism and Regulatory Peptides. Dr. Maggio has edited and co-authored a number of books and scientific articles in the biotechnology area and is an author of more than 60 issued and pending US and foreign patents.

Related Taxonomy
Popularity:
This record has been viewed 6324 times.



















- SHL


Click here to see the showcases


RDD (Respiratory Drug Delivery)
April 25-28
Nice, France

Pre-filled Syringes East Coast
April 26-27
Boston, MA


AAPS National Biotechnology Meeting
May 1-3
San Diego, CA

Innovation Networking Summit & Table-top Exhibition
May 4-5
Hilton Hotel, Parsippany, NJ

CPhI North America & Informex
May 16-18
2017 Philadelphia, PA

Pre-filled Syringes West Coast
June 5th & 6th, San Diego, USA

Peptides
July 6-7
London, United Kingdom 


BIO 2017

June 19 - 22
San Diego, CA

Controlled Release Society Meeting
July 16-19 Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Nienna, Austria

AAPS
November 12-17
San Diego, CA

 



Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions